Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award
November 13 2019 - 7:00AM
Business Wire
Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the
Company), a biopharmaceutical company focused on developing and
commercializing medicines seeking to improve the survival and
quality of life of cancer patients, today announced that Andrei
Shustov, M.D., Professor of Medicine and Hematology, University of
Washington, Associate Member, Clinical Research Division, Fred
Hutchinson Cancer Research Center and President and Founder of the
T-Cell Leukemia and Lymphoma Foundation (TCLLF) has been selected
to receive the Company’s Innovation in Care Award.
The Verastem Oncology Innovation in Care Award recognizes
individuals, organizations or teams who are leading the way in
advancing the principles of patient-focused care, including
coordination and integration of care, engaging patients, families,
and caregivers in providing comprehensive support as well as
collaborating with others in the cancer care system for ongoing
quality improvement.
“Recognizing a critical lack of resources available to those
affected by T-cell leukemias and lymphomas, Dr. Shustov has
dedicated his career to breaking new ground to expand support and
research efforts to those affected by these diseases,” said Brian
Stuglik, Chief Executive Officer of Verastem Oncology. “As a
company, we aim to follow the example of leaders like Dr. Shustov
as we not only seek to deliver therapies that keep cancer at bay,
but also continually look to innovate to improve the lives of those
diagnosed with cancer.”
The TCLLF is committed to providing reliable, accurate and
quality resources to patients, family members, caregivers and
medical professionals looking to learn more about T-cell leukemias
and lymphomas. Its patient education forums give direct access to
T-cell leukemia/lymphoma specialists, which allows them the
opportunity to learn more about their specific disease and ask
personalized questions. The Foundation has also recently started
sponsoring an annual T-Cell Leukemia/Lymphoma Young Investigator
Grant with the goal of producing valuable research efforts and
encouraging new oncologists/hematologists to specialize in the
treatment of these diseases.
“Patients and their families affected by rare lymphoid
malignancies like T-cell lymphomas have very limited resources
available to them to learn about their disease and its management.
With knowledge comes hope and power to take charge in making
important decisions regarding one’s life, and all patients deserve
that,” said Dr. Shustov. “The fight with cancer, like lymphomas,
only begins in the doctor’s offices and treatment centers; the real
challenge faces patients and families at home. This aspect of
patient care always felt missing. Filling this gap and providing
patients with education, access to expert opinions, and opportunity
to connect with other patients and families, were the inspirations
behind the founding of TCLLF.”
The Verastem Oncology Innovation in Care Award will be presented
to Dr. Shustov at a Verastem Oncology reception on December 6, 2019
during the American Society of Hematology (ASH) meeting in Orlando,
FL. Last year, the inaugural award recipient was Brian Koffman,
M.D., founder and volunteer Medical Director of the nonprofit CLL
Society (CLLS). Since his own CLL diagnosis in 2005, Dr. Koffman
has dedicated himself to teaching and advocating on behalf of the
CLL community.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of medicines to improve the lives of patients
diagnosed with cancer. We are driven by the strength, tenacity and
courage of those battling cancer – single-minded in our resolve to
deliver new therapies that not only keep cancer at bay but improve
the lives of patients diagnosed with cancer. Because for us, it’s
personal.
Our first FDA approved product is now available for the
treatment of patients with certain types of indolent non-Hodgkin’s
lymphoma (iNHL). Our pipeline comprises product candidates that
seek to treat cancer by modulating the local tumor
microenvironment. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191113005067/en/
Investors: John Doyle Vice President, Investor Relations &
Finance +1 781-469-1546 jdoyle@verastem.com
Media: Lisa Buffington Corporate Communications +1 781-292-4205
lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024